Nymox Pharmaceutical Corporation (NYMXF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nymox Pharmaceutical Corporation (NYMXF). Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on developing treatments for aging-related conditions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Nymox Pharmaceutical Corporation (NYMXF) Healthcare & Pipeline Overview
Nymox Pharmaceutical Corporation, a biopharmaceutical firm, specializes in developing treatments for aging-related conditions, with a primary focus on Fexapotide Triflutate (NX-1207) for benign prostatic hyperplasia and prostate cancer. The company also markets diagnostic products and explores Alzheimer's disease treatments, operating within the competitive biotechnology sector.
Investment Thesis
Nymox Pharmaceutical Corporation presents a speculative investment opportunity within the biotechnology sector, primarily driven by the potential success of its lead drug candidate, Fexapotide Triflutate (NX-1207). The drug's progress in clinical trials for BPH and low-grade localized prostate cancer is a key value driver. Positive clinical trial results and subsequent regulatory approvals could significantly increase the company's market capitalization. However, the company's high beta of 8.90 indicates significant volatility. The absence of a dividend further emphasizes the speculative nature of this investment, as returns are solely dependent on capital appreciation. The company's ability to secure partnerships and funding for further research and development is also crucial for its long-term success. Investors should carefully consider the risks associated with clinical trial outcomes, regulatory hurdles, and market competition before investing in NYMXF.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion reflects its small-cap status and potential for high growth but also higher risk.
- Negative P/E ratio of -3.30 indicates the company is currently not profitable, common for development-stage biopharmaceutical companies.
- High beta of 8.90 suggests the stock is significantly more volatile than the overall market.
- Lead drug candidate, Fexapotide Triflutate (NX-1207), is in clinical trials for BPH and low-grade localized prostate cancer, representing a key potential value driver.
- The company also develops and markets NicAlert and TobacAlert, providing some revenue diversification.
Competitors & Peers
Strengths
- Lead drug candidate (NX-1207) in clinical trials.
- Existing diagnostic products generating revenue.
- Focus on unmet medical needs in aging population.
- Experienced management team.
Weaknesses
- Limited financial resources.
- Dependence on success of NX-1207.
- High beta indicating significant volatility.
- Lack of profitability.
Catalysts
- Ongoing: Clinical trial results for Fexapotide Triflutate (NX-1207) in BPH and low-grade localized prostate cancer.
- Upcoming: Potential regulatory submissions for NX-1207 in various markets.
- Ongoing: Development and commercialization of new diagnostic products.
- Ongoing: Progress in preclinical studies for hepatocellular carcinoma.
- Ongoing: Advancement of Alzheimer's disease drug development program.
Risks
- Potential: Clinical trial failures for Fexapotide Triflutate (NX-1207).
- Potential: Regulatory hurdles and delays in obtaining approvals.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and dependence on external funding.
- Potential: Patent expirations and loss of intellectual property protection.
Growth Opportunities
- Expansion of Fexapotide Triflutate (NX-1207) indications: Nymox has the opportunity to expand the use of NX-1207 beyond BPH and low-grade localized prostate cancer. Preclinical studies for hepatocellular carcinoma suggest potential in a larger oncology market. Success in these studies and subsequent clinical trials could significantly increase the drug's market potential, addressing a global market projected to reach $25 billion by 2030.
- Strategic partnerships and collaborations: Nymox can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Collaborations can provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its products to market. The pharmaceutical industry is characterized by frequent collaborations, with deal values often exceeding hundreds of millions of dollars.
- Geographic expansion: Nymox can expand its geographic presence by seeking regulatory approvals and establishing commercial operations in new markets. Emerging markets, such as China and India, offer significant growth potential due to their large populations and increasing healthcare spending. Entering these markets requires navigating local regulatory requirements and establishing distribution channels.
- Development of new diagnostic products: Nymox can leverage its expertise in diagnostic testing to develop and commercialize new products for detecting various health conditions. The market for diagnostic tests is growing rapidly, driven by increasing awareness of preventive healthcare and technological advancements. Focus on areas such as early cancer detection or personalized medicine could provide significant growth opportunities.
- Advancement of Alzheimer's disease program: Nymox is developing drugs for the treatment of Alzheimer's disease, a significant unmet medical need. Success in this area could be transformative for the company. The Alzheimer's disease market is projected to reach $12 billion by 2028, driven by the aging global population and the increasing prevalence of the disease. However, Alzheimer's drug development is notoriously challenging, with a high failure rate.
Opportunities
- Expansion of NX-1207 indications.
- Strategic partnerships and collaborations.
- Geographic expansion into new markets.
- Development of new diagnostic products.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Patent expirations.
Competitive Advantages
- Patented drug formulations and technologies.
- Proprietary diagnostic tests.
- Clinical trial data and regulatory approvals (if obtained).
- Expertise in developing treatments for aging-related conditions.
About NYMXF
Founded in 1989 and headquartered in Nassau, Bahamas, Nymox Pharmaceutical Corporation is a biopharmaceutical company dedicated to the research and development of innovative therapies targeting the aging population. The company's primary focus is on addressing unmet medical needs in areas such as benign prostatic hyperplasia (BPH), low-grade localized prostate cancer, and Alzheimer's disease. Nymox's lead drug candidate, Fexapotide Triflutate (NX-1207), is currently undergoing various clinical trials for the treatment of BPH and low-grade localized prostate cancer. Additionally, preclinical studies are underway to explore its potential in treating hepatocellular carcinoma. Beyond pharmaceutical development, Nymox also develops and markets diagnostic products, including NicAlert, a test for detecting tobacco product usage, and TobacAlert, a test for detecting second-hand smoke exposure. These diagnostic tools complement the company's broader focus on health and wellness. Nymox operates internationally, with activities in Canada, the United States, Europe, and other regions. The company's strategy involves a combination of internal research and development efforts, as well as potential partnerships and collaborations to advance its pipeline and expand its market reach. Nymox faces competition from other biotechnology and pharmaceutical companies developing treatments for similar indications. The company's success depends on the successful completion of clinical trials, regulatory approvals, and commercialization of its products.
What They Do
- Develops pharmaceutical drugs for aging-related conditions.
- Focuses on treatments for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer.
- Conducts clinical trials for its lead drug candidate, Fexapotide Triflutate (NX-1207).
- Develops and markets diagnostic products for detecting tobacco usage and second-hand smoke exposure.
- Engages in preclinical studies for hepatocellular carcinoma.
- Develops drugs for the treatment of Alzheimer's disease.
- Operates internationally, including in Canada, the United States, and Europe.
Business Model
- Develops and patents pharmaceutical products.
- Conducts clinical trials to gain regulatory approval.
- Markets and sells diagnostic products.
- Potentially licenses or partners with other companies for drug commercialization.
Industry Context
Nymox Pharmaceutical Corporation operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for BPH and prostate cancer treatments is substantial and growing, driven by the aging global population. Nymox competes with established pharmaceutical companies and other biotechnology firms developing therapies for similar indications. The success of Nymox depends on its ability to differentiate its products, navigate the regulatory landscape, and secure partnerships to support its research and commercialization efforts. The biotechnology industry is subject to significant regulatory oversight, particularly from the FDA in the United States and the EMA in Europe.
Key Customers
- Patients with benign prostatic hyperplasia (BPH).
- Patients with low-grade localized prostate cancer.
- Individuals concerned about tobacco usage and second-hand smoke exposure.
- Healthcare providers and institutions.
Financials
Chart & Info
Nymox Pharmaceutical Corporation (NYMXF) stock price: Price data unavailable
Latest News
No recent news available for NYMXF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NYMXF.
Price Targets
Wall Street price target analysis for NYMXF.
MoonshotScore
What does this score mean?
The MoonshotScore rates NYMXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Paul Averback
CEO
Paul Averback serves as the Chief Executive Officer of Nymox Pharmaceutical Corporation. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive background profile cannot be constructed. Further research beyond the provided data would be necessary to provide a complete overview of Mr. Averback's professional journey.
Track Record: Information regarding Paul Averback's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. Therefore, a detailed assessment of his track record cannot be provided. Further research beyond the provided data would be necessary to evaluate his performance as CEO of Nymox Pharmaceutical Corporation.
NYMXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nymox Pharmaceutical Corporation may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information, price volatility, and illiquidity. These stocks may not be required to adhere to strict reporting standards, increasing the risk of fraud or misrepresentation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or misrepresentation.
- Limited liquidity and wider bid-ask spreads.
- Less regulatory oversight compared to exchange-listed companies.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review any legal or regulatory issues facing the company.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 1989.
- Lead drug candidate in clinical trials.
- Develops and markets diagnostic products.
- Focuses on addressing unmet medical needs.
NYMXF Healthcare Stock FAQ
What does Nymox Pharmaceutical Corporation do?
Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapies and diagnostic products for the aging population. Their lead drug candidate, Fexapotide Triflutate (NX-1207), is in clinical trials for the treatment of benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The company also develops and markets diagnostic tests, such as NicAlert and TobacAlert, for detecting tobacco usage and second-hand smoke exposure. Nymox operates internationally, with a focus on addressing unmet medical needs in areas such as urology, oncology, and Alzheimer's disease.
What do analysts say about NYMXF stock?
Due to the limited information available and the company's OTC listing, analyst coverage of NYMXF is likely minimal or non-existent. Key valuation metrics, such as price targets and earnings estimates, are unlikely to be readily available. Investors should conduct their own thorough research and consider the risks associated with investing in a small-cap, development-stage biopharmaceutical company traded on the OTC market. Growth considerations primarily revolve around the successful development and commercialization of Fexapotide Triflutate (NX-1207) and other pipeline candidates.
What are the main risks for NYMXF?
The main risks for Nymox Pharmaceutical Corporation include the potential for clinical trial failures, regulatory hurdles and delays, competition from established pharmaceutical companies, limited financial resources, and dependence on external funding. The company's success is heavily reliant on the successful development and commercialization of Fexapotide Triflutate (NX-1207). Failure to obtain regulatory approvals or competition from other therapies could significantly impact the company's prospects. Additionally, the company's OTC listing and limited financial disclosure increase the risk of price manipulation and fraud.
What are the key factors to evaluate for NYMXF?
Evaluating NYMXF involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Lead drug candidate (NX-1207) in clinical trials.. Primary risk to monitor: Potential: Clinical trial failures for Fexapotide Triflutate (NX-1207).. This is not financial advice.
How frequently does NYMXF data refresh on this page?
NYMXF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NYMXF's recent stock price performance?
Recent price movement in Nymox Pharmaceutical Corporation (NYMXF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Lead drug candidate (NX-1207) in clinical trials.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NYMXF overvalued or undervalued right now?
Determining whether Nymox Pharmaceutical Corporation (NYMXF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NYMXF?
Before investing in Nymox Pharmaceutical Corporation (NYMXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be incomplete.
- OTC market investments carry higher risk.
- AI analysis pending for NYMXF.